Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

By LabMedica International staff writers
Posted on 17 Sep 2026

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. More...

These templates capture information needed for diagnosis, staging, and treatment while aligning with expert guidance. To support this work, the College of American Pathologists has detailed Cancer Protocol updates addressing breast cancer biomarker reporting and gastrointestinal stromal tumor molecular testing.

The College of American Pathologists (CAP) has introduced revisions to 14 Cancer Protocols to align cancer reporting with evolving World Health Organization (WHO) classifications and advances in precision medicine. The Q3 release focuses on breast cancer biomarkers and gastrointestinal stromal tumors (GISTs). According to CAP, the updates reflect advances in precision oncology and laboratory accreditation.

CAP’s Cancer Protocols are updated quarterly to incorporate guidance from leading standard-setting organizations, including the WHO and the American Joint Committee on Cancer (AJCC). These evidence-based tools are designed to help pathologists produce accurate, standardized reports that support diagnosis, staging, treatment decisions, and patient care. A full Summary of Revisions is available on cap.org.

Among the most significant changes, the Breast Phyllodes Tumor protocol is now required for accreditation when reporting malignant phyllodes tumors. The revised protocol incorporates WHO 6th Edition updates, modifies specific reporting elements, and updates staging and margin reporting. CAP notes that these changes are intended to bring reporting into closer alignment with current classifications.

The release also updates the Breast Biomarker Protocol, including revisions to estrogen receptor (ER), progesterone receptor (PgR), and HER2 scoring and reporting criteria. These changes are designed to support consistent reporting of biomarkers that help guide breast cancer treatment decisions. In addition, CAP expanded molecular testing and reporting capabilities within its GIST protocols, adding new reporting options for NTRK fusion gene analysis, enhancing KIT and PDGFRA testing and reporting, and supporting reporting for GISTs across all anatomic sites.

Related Links
College of American Pathologists


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.